American journal of clinical and experimental immunology最新文献

{"title":"Comprehensive comparison of theranostic nanoparticles in breast cancer.","authors":"Amin Nikdouz,&nbsp;Nima Namarvari,&nbsp;Ramin Ghasemi Shayan,&nbsp;Arezoo Hosseini","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Breast cancer is the most frequently happening cancer and the most typical cancer death among females. Despite the crucial progress in breast cancer therapy by using Chemotherapeutic agents, most anti-tumor drugs are insufficient to destroy exactly the breast cancer cells. The noble method of drug delivery using nanoparticles presents a great promise in treating breast cancer most sufficiently and with the least harm to the patient. Nanoparticles, with their spectacular characteristics, help overcome problems of this kind. Unique features of nanoparticles such as biocompatibility, bioavailability, biodegradability, sustained release, and, most importantly, site-specific targeting enables the Chemotherapeutic agents loaded in nanocarriers to differentiate between healthy tissue and cancer cells, leading to low toxicity and fewer side effects. This review focuses on evaluating and comprehending nanoparticles utilized in breast cancer treatment, including the most recent data related to the drugs they can carry. Also, this review covers all information related to each nanocarrier, such as their significant characteristics, subtypes, advantages, disadvantages, and chemical modification methods with recently published studies. This article discusses over 21 nanoparticles used in breast cancer treatment with possible chemical ligands such as monoclonal antibodies and chemotherapeutic agents binding to these carriers. These different nanoparticles and the unique features of each nanocarrier give the researchers all the data and insight to develop and use the brand-new drug delivery system.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"11 1","pages":"1-27"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938632/pdf/ajcei0011-0001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10269823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of pretreatment with dexamethasone on the efficacy and immune-related adverse events of immunotherapy in first-line treatment for advanced non-small cell lung cancer: a network meta-analysis of randomized control trials.","authors":"Yanwei Li,&nbsp;Feng He,&nbsp;Shuang Liu,&nbsp;Yu Zhang,&nbsp;Ling Li,&nbsp;Bin Wang,&nbsp;Lan Lan,&nbsp;Zhanyu Pan","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>The pretreatment of dexamethasone on the efficacy and immune-related adverse events of immunotherapy involving programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PDL1) inhibitors is an effective option for the first-line treatment of advanced non-small-cell lung cancer (NSCLC). With the immunosuppressive effect, corticosteroids may be used to reduce the efficacy of PDL1 blockade, as well as prevent overactive immune responses, thereby reducing the occurrence of immune-related adverse events (irAEs). This study quantitatively summarized the current evidence, and compared the efficacy and toxicity of therapies involving chemotherapy plus PDL1 inhibitors plus dexamethasone pretreatment (I+C+D) with chemotherapy plus PDL1 inhibitors (I+C) and therapies involving PDL1 inhibitors or chemotherapy alone (I or C).</p><p><strong>Methods: </strong>The protocol of this study was registered with PROSPERO (CRD42021227281). By using a network meta-analysis approach, the different treatments were compared and ranked based on their effectiveness and rates of irAEs at the different grades. Risk rates were determined through direct meta-analysis and indirect treatment comparison.</p><p><strong>Results: </strong>12 randomized clinical trials were included with a total of 7155 NSCLC patients. Network meta-analysis generated 15 comparisons. The combination treatment of I+C+D showed a longer progression-free survival and overall survival, while I+C was less toxic, and the toxicity of I+C+D or that of I+C had been significantly decreased, compared to that of monotherapy with either drug. According to the ranking analysis, I+C+D is consistently proved to be the most effective therapeutic strategy, while I+C is linked to the lowest rate of irAEs, with the rate of grade value of ≥3 irAEs.</p><p><strong>Conclusion: </strong>The combination treatment of I+C+D is the most effective approach for the first-line treatment of NSCLC patients treated with I+C, I, or C.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 4","pages":"93-102"},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784760/pdf/ajcei0010-0093.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39576989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum and salivary immunoglobulin G4 levels in children with autism spectrum disorder from south India: a case-control study.","authors":"Sham Subraya Bhat,&nbsp;Bhuvanesh Sukhlal Kalal,&nbsp;Korikkar Mahaling Veena,&nbsp;Anil Kakunje,&nbsp;Kaupu Sathish Rao Sahana,&nbsp;Punchappady Devasya Rekha,&nbsp;Jagadish Chandra,&nbsp;Irshad Nasreen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with wide spectrum of symptoms and few effective therapies. Evidence is suggestive of an association between immune system dysfunction and autism spectrum disorders (ASD) among children with ASD. Immunoglobulins (Ig) are found to be increased in the circulation of individuals with autism. The prospective study was aimed to estimate and correlate the levels of IgG4 in blood and saliva of children with autism.</p><p><strong>Methodology: </strong>Blood and unstimulated saliva were collected from 172 children (55 ASD, 57 healthy control, and 60 suspected parasitic infection) aged 0-18 years. Routine blood investigations were done. Serum and salivary IgG4 levels were analyzed using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Data were subjected to statistical analysis.</p><p><strong>Results: </strong>ELISA tests showed that the IgG4 levels in serum and saliva were significantly increased (P<0.05) in children with ASD as compared to normal control children. Both serum and saliva IgG4 levels showed a significant positive correlation (P<0.05).</p><p><strong>Conclusion: </strong>IgG4 can be used as a potential biomarker for the early detection of ASD. Further, saliva can be a diagnostic, noninvasive assessment tool for health monitoring of children with autism. Lay summary: The collection of saliva is easy and painless compared to other sample collection methods. The present study shows that, among children with autism, brain-reactive antibody, immunoglobulin G4 (gG4), is increased both in blood and saliva, and there is a significant correlation between the two levels. Therefore, the study recommends IgG4 as a potential biomarker for the early detection of autism, and saliva can be helpful in diagnosis and health monitoring of children with ASD.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 4","pages":"103-111"},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784761/pdf/ajcei0010-0103.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39576990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence and clinical manifestations of IgA deficiency among blood donors at transfusion centers in Shiraz, Southern Iran.","authors":"Seyed Hesamedin Nabavizadeh,&nbsp;Mohammad Hossein Karimi,&nbsp;Hossein Esmaeilzadeh,&nbsp;Maryam Attarhoseini,&nbsp;Aida Askarisarvestani","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>IgA deficiency is the most common immunodeficiency disorder. Most affected individuals are asymptomatic, and since there are no routine diagnostic screening programs the prevalence of this disease has remained uncertain.</p><p><strong>Methods and materials: </strong>Seven thousand blood donors who attended Fars Blood Transfusion Center, from September 2017 to March 2018, were selected randomly, and their serum IgA levels were checked by Immunoturbidimetry method. Cases with IgA levels <10 mg/dL were considered as serum IgA deficient patients. Serum IgM and IgG levels of IgA deficient cases were measured to determine selective IgA deficiency. The prevalent clinical findings of IgA deficiency were also investigated.</p><p><strong>Results: </strong>Ten blood donors had selective IgA deficiency: 0.14% (CI 95%: 0.001, 0.002). All cases were male, with a mean age of 36.10±9.70 years. Investigating common clinical findings in the IgA deficient cases revealed the most prevalent symptoms were recurrent upper respiratory tract infections (50%) which were significantly higher in the study group compared to the control group (<i>P</i>-value =0.008) and allergic disorders (40%) with no statistical difference from the control cases.</p><p><strong>Conclusion: </strong>The prevalence of selective IgA deficiency (SIgAD) among blood donors at Fars Transfusion Center was 0.14%. The most common clinical finding among the patients with SIgAD was recurrent upper respiratory infections, followed by allergic diseases.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 4","pages":"112-116"},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784762/pdf/ajcei0010-0112.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39576991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TLR8 is highly conserved among the Saudi population and its mutations have no effect on the severity of COVID-19 symptoms.","authors":"Waleed H Mahallawi,&nbsp;Bandar A Suliman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Coronavirus 2019 (COVID-19) is an infection caused by the newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The innate system is the first line of defense against pathogens and diverse infectious agents. It has been suggested to play a key role in the development of the cytokine storm and promoting other severe forms of chronic inflammation. Toll-like receptors (TLRs) are crucial for the innate immune response to pathogens. TLR8 is expressed on myeloid cells and phagocytes, where it acts as an endosomal sensor of RNA degradation. The present study aimed to investigate whether the severity of COVID-19 symptoms could be associated with certain genetic variations of TLR8. We collected blood samples from 45 participants who had moderate to severe respiratory symptoms and a positive COVID-19 PCR test result within 3-5 days of sample collection. Genomic DNA was extracted from the blood samples, then exon 2 of the TLR8 gene was amplified with polymerase chain reaction (PCR), and PCR products were utilized for sequencing. DNA sequencing showed an average of 99.63% sequence homology in TLR8 across all samples. Base-pair homology analysis revealed variations in TLR8 at two positions: X:12937804 (rs5744080) and X:12937513 (rs2159377). The results revealed that these two mutations had no detrimental effect on symptoms in the target population. Our results show that specific SNPs did not affect the final receptor function of TLR8. This finding also indicates that the innate immune response, once activated, does not depend on the innate immune receptor's level of affinity for identifying their respective glycoprotein structures on the SARS-CoV-2 virus.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 3","pages":"71-76"},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610803/pdf/ajcei0010-0071.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39772565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunological mechanisms of scarring and their psychological impact on patients.","authors":"Wenke Shen, Wenyun Xu, Hui Chen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A scar is a local symptom, which results from severe physical, biological and chemical damage to human skin and soft tissue. Scars can affect both skin appearance and function. The affected skin or soft tissue cannot be completely repaired normally by itself and is replaced by formed fibrous tissue. Patients with scars can develop physical pain and mental conditions, especially those with scars left after burns, scalds and severe traumas. The scar proliferation phase can be up to several years which could be almost unbearable for patients. Also, the atrophic period afterwards makes the patient's face unrecognizable and dysfunctional, causing great physical and mental impairment. Therefore, scar repair is of great clinical importance for patients, and understanding the immunological mechanisms of scar repair is an important prerequisite for the effective treatment of scars. This study is a systematic review of current research advances about the immunological mechanisms of scar repair, so as to provide a reference for the selection of regimens in clinical treatment.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 3","pages":"65-70"},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610804/pdf/ajcei0010-0065.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39772564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of fingolimod versus dimethyl fumarate for the treatment of multiple sclerosis; a 24-month follow-up study.","authors":"Samane-Sadat Masjedi,&nbsp;Masoud Etemadifar,&nbsp;Nadia Mohammad Zadeh,&nbsp;Mahdieh Afzali","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Oral treatment of multiple sclerosis (MS) using disease-modifying therapies (DMTs) is a challenge worldwide. Fingolimod (FTY) and dimethyl fumarate (DMF) are two approved agents for oral treatment of MS with remarkable efficacy for relapse control and deceleration of disability progression. Therefore, the current study was done to compare disability control, lesions in magnetic resonance imaging (MRI), and adverse effects between the patients treated with FTY and DMF.</p><p><strong>Methods: </strong>This randomized clinical trial (IR.MUI.REC.1396.3.786) was conducted on 60 patients who were randomly divided into two groups of treatment with 0.5 mg daily dose of FTY (n = 30) and 240 mg dose of DMF twice daily (n = 30). Disability of patients was assessed using the expanded disability status scale (EDSS) within 6 weeks, 12, and 24 months following treatment initiation and MRI was performed for all the patients prior to study initiation and within 24 months. Obtained data were compared between two study groups.</p><p><strong>Results: </strong>There was no significant difference between two treatment groups based on EDSS scores, brain lesions in MRI, and newly formed plaques (P>0.05). Skin and gastrointestinal-related complaints were the most common adverse effects of DMF while the increase in liver enzyme level and thrombocytopenia were the most common complications of FTY, respectively (<i>P</i>-value = 0.22).</p><p><strong>Conclusion: </strong>According to our findings, within 24-month follow-up, DMF was neither superior nor inferior to FTY comparing MRI lesions, EDSS scores, and adverse effects. Although, further evaluations with larger sample size are recommended.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 3","pages":"86-92"},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610802/pdf/ajcei0010-0086.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39772567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 in children with inborn errors of immunity: clinical scenarios.","authors":"Nasrin Moazzen,&nbsp;Hamid Ahanchian,&nbsp;Mohammad Hassan Aelami,&nbsp;Hajar Asiyon,&nbsp;Mojgan Astaneh,&nbsp;Amirhossein Masrour Naeimi,&nbsp;Nima Rezaei","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The new emerging virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes a huge burden of morbidity and mortality worldwide. One of the predisposing factors which might increase the infection susceptibility and its complications can be the Inborn Errors of Immunity (IEI). One hundred and seventeen primary immunodeficient (PID) pediatric patients were monitored from March to December 2020 for any signs and symptoms of SARS-CoV-2 infection. Among them twenty-eight children were symptomatic and nineteen out of the twenty-eight patients took the coronavirus PCR test. Out of them, the PCR test results of 9 patients were positive. Herein, we report the nine cases of pediatric patients with IEI who were also infected with SARS-CoV-2 with a positive PCR test. We observed a variation in clinical manifestations, clinical courses, and outcomes among IEI pediatric patients affected with COVID-19. In our survey, prompt diagnosis and appropriate monitoring for possible complications were shown to be effective in reducing the mortality rate of the SARS-CoV-2 affected patients with IEI. Although there is no approved treatment for SARS-CoV-2 infection, supportive treatment might reduce the complications and lead to better outcomes. This study received approval from the Research Ethics Committee of Mashhad University of Medical Science with the ethics code of IR.MUMS.REC.1399.155. (https://ethics.research.ac.ir/EthicsProposalViewEn.php?id=129963).</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 3","pages":"77-85"},"PeriodicalIF":0.0,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610801/pdf/ajcei0010-0077.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39772566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: X-linked agammaglobulinemia: investigation of clinical and laboratory findings, novel gene mutations and prevention of infective complications in long-term follow-up.","authors":"İlke Yıldırım,&nbsp;Ezgi Topyıldız,&nbsp;Raziye Burcu Güven Bilgin,&nbsp;Ayça Aykut,&nbsp;Asude Durmaz,&nbsp;Neslihan Edeer Karaca,&nbsp;Guzide Aksu,&nbsp;Necil Kutukculer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>[This corrects the article on p. 37 in vol. 10, PMID: 33815962.].</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 2","pages":"63-64"},"PeriodicalIF":0.0,"publicationDate":"2021-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449154/pdf/ajcei0010-0063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39467722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy evaluation of acupotomy combined with platelet-rich plasma in the treatment of early and middle osteoarthritis.","authors":"Yong Wang,&nbsp;Aimin Yang,&nbsp;Shuai Dai","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy of traditional Chinese medicine acupotomy combined with platelet-rich plasma (PRP) in the treatment of early and middle osteoarthritis.</p><p><strong>Methods: </strong>Eighty cases of early and middle knee joint pain patients admitted in our hospital were selected in this retrospective study. They were divided into the control group and observation group according to treatment methods, with 40 cases in each group. The control group was treated with PRP, and the observation group was treated with acupotomy + PRP. Clinical response rate, visual analogue scale (VAS) pain score, Lequesne score, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index and SF-36 quality of life score were compared between the two groups.</p><p><strong>Results: </strong>The total clinical response rate in the observation group was higher than that in control group (P<0.01). VAS pain score, knee joint WOMAC index and Lequesne score in the two groups after treatment were lower than those before treatment, and those in the observation group were lower than those in the control group (all P<0.05). SF-36 quality of life score was significantly higher in the observation group than in the control group (all P<0.001).</p><p><strong>Conclusion: </strong>Acupotomy combined with PRP in the treatment of early and middle osteoarthritis can relieve pain and improve joint function, which is worthy of clinical promotion.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"10 2","pages":"48-55"},"PeriodicalIF":0.0,"publicationDate":"2021-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449153/pdf/ajcei0010-0048.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39467720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}